Danaher Corporation
DHR
Positions held
Your positionsDHR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Danaher Corporation operates in a competitive healthcare diagnostics market, leveraging its strong portfolio of brands to maintain a leadership position.
- In the most recent quarter, Danaher reported a revenue increase of 5% compared to the prior quarter, reaching $6.3 billion.
- Despite a slight compression in gross margin to 57.6%, the company maintains a robust operating margin of 18%.
- The healthcare diagnostics industry is subject to regulatory changes that could impact Danaher's operational flexibility and profitability.
- Danaher's gross margin decreased from 60.3% in the previous quarter to 57.6%, indicating potential cost pressures.
- The operating margin has also compressed to 18%, down from 22.6% in the prior quarter, suggesting challenges in maintaining profitability.
Fundamentals
| Market cap | $152.87B | Enterprise value | $176.39B | Trailing P/E | 38.76 | Forward P/E | 23.39 |
| PEG | 1.31 | Price / book | 2.91 | Beta | 0.80 | Dividend yield | 0.74% |
| Revenue growth | 5.5% | Earnings growth | 59.7% | Gross margin | 58.8% | Operating margin | 19.8% |
| Profit margin | 15.9% | ROE | 7.6% | ROA | 3.9% | Debt / equity | 0.53 |
| Current ratio | 1.65 | Free cash flow | $4.33B | Analyst recommendation | strong_buy | Mean target | $239.86 |
| 52w high | $242.80 | 52w low | $160.93 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $6.3B | $6.0B | $6.8B | $6.1B | $5.9B |
| Op margin | 18.0% | 22.6% | 22.0% | 19.1% | 12.8% |
| Net income | $870M | $1.0B | $1.2B | $908M | $555M |
| Gross margin | 57.6% | 60.3% | 58.0% | 58.2% | 59.3% |
| Gross profit | $3.6B | $3.6B | $4.0B | $3.5B | $3.5B |
| Operating income | $1.1B | $1.3B | $1.5B | $1.2B | $760M |
- Revenue +5% vs prior quarter ($6.3B vs $6.0B).
- Gross margin 57.6% (was 60.3% prior quarter).
- Operating margin compressed to 18%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $24.6B | $23.9B | $23.9B | $26.6B | — |
| Op margin | 19.1% | 20.4% | 21.8% | 28.3% | — |
| Net income | $3.6B | $3.9B | $4.8B | $7.2B | — |
| Gross margin | 59.1% | 59.5% | 58.7% | 60.8% | — |
| Gross profit | $14.5B | $14.2B | $14.0B | $16.2B | — |
| Operating income | $4.7B | $4.9B | $5.2B | $7.5B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Did Danaher’s (DHR) New AI-Powered Autonomous Lab at Abcam Just Redefine Its Innovation Edge?
2026-10-08 · Danaher (DHR) Stock May Be 4% Undervalued Despite AI Lab Launch
2026-10-08 · Is Danaher (DHR) Undervalued As Its New AI Lab Pushes Faster Antibody Development?
2026-10-08 · Danaher (DHR) Launched Its First AI Powered Autonomous Laboratory
2026-10-08 · Baird Adjusts Price Target on Danaher to $246 From $238
2026-10-07 · Top Stock Reports for AMD, Palo Alto & ConocoPhillips
2026-10-07 · Evercore ISI Adjusts Price Target on Danaher to $240 From $205
2026-10-07 · Danaher launching AI-powered autonomous lab for drug discovery
2026-10-07 · Apple ordered to pay Masimo $184M in interest on patent damages
2026-10-07 · Danaher stock rises 2% on AI-powered autonomous lab plans
2026-10-07 · Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday
2026-10-07 · Sector Update: Healthcare
Price (daily)
Full chart · RSI · MACD · patterns